Frost & Sullivan and LeadLeo Release White Paper on China's Industrial Trends

The document, grounded in the new industrial cycle of China's 15th Five-Year Plan, provides a comprehensive analysis of the technological evolution, market growth potential, and structural transformation of China's core industries over the next five decades. The industries covered include Artificial Intelligence (AI), Intelligent Manufacturing, Mass Consumption, Healthcare, and Semiconductors.

The white paper highlights the shift in these industries from single-point technological breakthroughs to systematic capability building, from follow-the-leader innovation to pioneering layout, and from commodity export to ecosystem co-construction. In the realm of AI, China has established a complete industrial system, with a growing number of enterprise registrations and patent applications. The massive internet user base and intelligent computing infrastructure serve as a unique application testbed. The performance gap between top-tier Chinese and U.S. AI models has narrowed to the low single-digit range, and agent technology is driving AI from content generation into task execution. Enterprise-grade agents are being embedded into core business processes, while consumer-grade agents are reshaping interaction entry points for search, learning, and office productivity.

In the field of Intelligent Manufacturing, China's manufacturing output has ranked first globally for sixteen consecutive years. The intelligent manufacturing equipment sector is expanding, and the number of Lighthouse Factories leads the world. The digitalization rates of critical processes and R&D design tools have improved significantly, laying a solid foundation for advancing toward Industry 4.0. Intelligent transformation is deepening, with AI and digital twin technologies shifting the focus of smart factory construction from the perception layer toward the cognitive and decision-making layers. Flexible manufacturing and C2M models are accelerating deployment, and the indigenous competitiveness of industrial robots is strengthening. The policy system is providing comprehensive empowerment, spanning infrastructure, legal safeguards, and consumption scenarios.

The Mass Consumption industry is experiencing a deep structural transition from scale expansion to quality migration. Total retail sales of consumer goods continue to expand, and urban-rural consumption synergy is clearly trending. The scale of the middle-income group ranks among the world's largest, with ample room for consumption-rate improvement relative to developed economies. The consumption structure is shifting from survival-oriented to development- and enjoyment-oriented consumption, with the share of service consumption in total expenditure trending upward and the overall Engel coefficient declining. Digital technology is reshaping supply logic from batch-defined standardized products toward responsive personalization. AI agents are reconstructing supply-chain decision-making, while flexible capacity and C2M models are shifting production logic from production-driven sales to demand-driven production. Consumption entry points are adjusting from platform concentration toward scenario dispersion, with instant retail and proximity commerce reshaping the human-goods-venue logic.

In the Healthcare industry, China is transitioning from undifferentiated scale expansion of generic drugs toward original innovation and global commercialization synergy. Indigenous innovative R&D capabilities are rising rapidly, with the scale of drug pipelines under development ranking among the world's highest. Domestic chemical and biological new drug IND filings are growing steadily, and frontier tracks such as ADC and cell therapy are comprehensively deployed. Optimization of the drug review and approval system has fostered a development pattern featuring accelerated innovative drug translation, quality-upgraded generic drug expansion, and legacy product upgrading in parallel. A six-pillar linked policy support system constitutes a full-cycle business environment. The industrial chain has formed a complete three-tier architecture: upstream underlying technology platforms, midstream production and manufacturing, and downstream medical services and health operations. Innovative drug out-licensing transactions continue to expand, with China transitioning from a net importer of overseas technology to a global core technology exporter. Synthetic Biology is achieving scaled commercialization in healthcare ahead of other sectors, and AI Medical Devices are becoming a core force in bridging medical resource gaps.

Finally, the Semiconductor industry is upgrading from single-chip supply toward full-chain synergy, encompassing computing systems, advanced packaging, equipment processes, and software ecosystems. Semiconductors are evolving from an information industry foundation to an underlying technology platform supporting AI computing, intelligent vehicles, industrial robots, and power electronics. The focus of domestic chip competition is shifting from basic substitution toward scenario-specific capability building, with software ecosystems and customer validation cycles becoming critical variables. Advanced Packaging is upgrading from back-end manufacturing to a system-level performance design function. Chiplet and heterogeneous integration enhance architectural flexibility, while 2.5D/3D and hybrid bonding technologies support high-density interconnection. China's regional ecosystems have formed a differentiated layout, with the Yangtze River Delta for manufacturing support, the Pearl River Delta for application translation, Beijing-Tianjin-Hebei for scientific research innovation, and the central and western regions for specialized manufacturing.

The white paper aims to serve as a valuable reference for industry participants, investors, and researchers in assessing long-term trends and formulating strategic decisions. It underscores the importance of China's continued investment in these core industries to propel its economy from scale expansion toward quality leapfrog development.